Cancure is a biopharmaceutical company founded in 2012, with the aim of investing in therapies capable of countering several major diseases afflicting society today.
Cancure has developed a suite of breakthrough oncology therapies, which employ innovative methods to enhance the body’s anti-cancer immune response, or kill cancer cells by exploiting novel targets within them. These revolutionary therapies are ideally positioned in the emerging fields of immuno-oncology, combination therapies and mitochondrial biology.
Cancure is developing these therapies into marketable drugs that push the limits of anti-cancer response rates and hasten the evolution of cancer treatments into cancer cures.
